Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

Completed · Not applicable

Conditions studied: Vulvar Cancer

In brief

RATIONALE: Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Applying topical imiquimod to the vulva may be an effective treatment for recurrent Paget's disease. PURPOSE: This clinical trial is studying how well topical imiquimod works in treating patients with recurrent Paget's disease of the vulva.

Key facts

Study ID

NCT00504023

Run by

Memorial Sloan Kettering Cancer Center

People needed

8

Starts

2007-04-01

Expected to finish

2018-01-01

Last updated by the study team

2018-06-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• All patients presenting to the Gynecology outpatient service at a participating institution who meet eligibility requirements may be included in this clinical trial. The eligibility requirements are as follows:
• Age ≥18.
• Ability to give informed consent.
• Patients must have biopsy proven recurrent extramammary Paget's disease confirmed at the participating site.

You may not qualify if…

• Patients with known hypersensitivity to imiquimod.
• Pregnant and nursing women are not eligible
• Patients with underlying adenocarcinoma on biopsy of lesion confirmed at the participating site.

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.